Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best
Currently, Ra Pharmaceuticals stock doesn't match any of these trading strategies, so our recommendation is not to buy now. This doesn't mean we expect a selloff for RARX in the next few days, or that it may not climb higher. Simply, it doesn't match our recommended trading systems
"To sell or not to sell", if you are holding Ra Pharmaceuticals shares?. Trading strategies let us to avoid impetuous decisions based on our personal sentiments or the noise that surrounds the market. Our trading system selects very simple strategies to guide us on when is a good time to sell our shares. Be aware that these strategies are not intended for selling short Ra Pharmaceuticals stock
A golden rule is that you should never hold a trading operation that results in higher than expected losses at the time of the buy. When to sell shares always has to be dictated by the stop-loss (automatic or manual)
Currently, Ra Pharmaceuticals stock doesn't match any of our preferred sell setups, so if you own Ra Pharmaceuticals stock and your operation is in profit probably is not time to sell now
Brokerage firms and financial institutions post stock ratings based on their views of the market and the fundamental and technical situation of the analyzed stock. Unfortunately, the accuracy of these predictions is not very high, and certainly not a direct buy or sell signal
In the last month we couldn't find any rating for Ra Pharmaceuticals
Ra Pharmaceuticals did it again, and reached new all-time highs (ATH) in late March at $48.02
A favorite tool of many technical analysts are the moving averages, that easily show market direction. A moving average is the average price of a stock over a set period of time. Moving averages are usually calculated on different periods depending on the trading timeframe 21, 50, 100 and 200 days are the most usual moving averages
Technical analysts use support and resistance levels as a way to find price points in the stock price action that tend to work as obstacles, containing the price of a stock to move up or down. Supports are levels where the price may find support as it falls. Price is more likely to "rebound" this level rather than break through it. However, if the price breaks down the support, it will probably continue falling until approaching another support level. On the other hand, resistance levels are where the price tends to find opposition as it rises. In the same way, the price is more liable to "rebound" at this level, and if it finally breaks this level, the price will rise easily until it hits the next resistance
Price is at highs and there are not upper resistance levels.
The current supports are:
So-called Bollinger bands are a widespread technique created by John Bollinger. It is composed of 3 bands that are superimposed on the price evolution chart:
The price is moving near to the upper Bollinger band, signaling some level of overbought in recent sessions. This is not a sell signal, as price can trade in these levels for many days and weeks
The Relative Strength Index is an oscillator-type indicator that track price changes to identify when the price of a share or financial asset is oversold or overbought. Like other oscillation indicators, the RSI fluctuates between 0% and 100%. The relative strength indicator is one of the best known and most widely used indicators, and it was invented by J. Welles Wilder in 1978
The RSI crossed up the oversold line of 30 in mid-March after just being in the oversold zone for 1 day (what can be considered a strength sign). The RSI reading in early April was 58.12. Since RSI left the oversold zone, Ra Pharmaceuticals shares exploded a 18.46%
RARX hosted the financial call and released the Q2 report on Wednesday. The consensus earnings estimate is a earnings of %s a share of $-0.65, that is a 1.52% less than previous reported quarter.
Same quarter last year, reported EPS was $-0.52, so recently posted EPS is a gain of 100%. Revenue only changed on an annualized basis in the second-quarter, from $0.00 to $3.0M last quarter.
RARX is hosting the quarterly earnings call. If you hold or you are thinking of buying RARX stock, you must be on your toes as financial reporting day usually has a higher than usual volatility, and price can gap up or down with unsually low liquidity and not respecting your buy/stop-loss orders.